Abstract
Objectives:
Despite drug overdose deaths increasing among peripartum persons, little is known about how to increase naloxone acceptance in this population. This study evaluated the effect of a brief 15-min computer facilitated personally-Tailored Opioid- overdose and Medication for opioid use disorder (MOUD) Educational intervention (TOME) on naloxone uptake and compared participant characteristics based on naloxone acceptance.
Methods:
This secondary analysis is from an outpatient randomized multisite trial with peripartum individuals receiving MOUD treatment. Participants were randomized to TOME or control. TOME participants met 1:1 with research staff to review a printout of missed pre-test opioid overdose and MOUD knowledge questions that explained the correct answer. Control participants received educational materials from the Substance Abuse and Mental Health Services Administration. Baseline demographics, treatment characteristics, opioid overdose and MOUD knowledge, and self-report MOUD stigma ratings were compared between participants who accepted versus declined free study-provided naloxone because they already had it or for other reasons. The intervention’s effect on naloxone acceptance was evaluated after delivery of TOME or control among those accepting versus those declining naloxone for other reasons.
Results:
Of 111 participants, 90 accepted naloxone, 14 declined due to already having naloxone, and seven declined for other reasons (e.g., not affiliating with people who would need it, not wanting it in their house, allergy). These three groups significantly differed on past stigma from family (p=0.007) and employers (p=0.013) whereby participants declining naloxone due to already having it had the lowest stigma. Those accepting naloxone (n=90) were nearly evenly split between TOME (n=48) and control (n=42). Six of the seven declining naloxone for other reasons were control participants. Among the 97 accepting naloxone or declining it for other reasons, TOME trended toward increasing naloxone acceptance (OR: 6.857, CI: 0.793, 59.291, Fisher Exact test p=0.0592). There was a higher percentage of correct MOUD answers in the 90 accepting naloxone (66.8%) vs. the 7 declining for other reasons (55.7%; p=0.0471).
Conclusions:
These preliminary results suggest the need for further work to determine if educational interventions can enhance naloxone acceptance and suggest that stigma and medication treatment knowledge may be important factors influencing naloxone acceptance.
Keywords: education, opioid use disorder, overdose, naloxone, peripartum
1. Introduction
As the United States (US) opioid epidemic continues, pregnancy-associated overdose mortality has increased. Average semiannual drug overdose deaths more than tripled among peripartum individuals aged 35–44 years from 2018–2021 (Han, Compton, Einstein, Elder, & Volkow, 2024). The Substance Abuse and Mental Health Services Administration (SAMHSA) and American College of Obstetrics and Gynecology (ACOG) recommend that pregnant individuals with opioid use disorder (OUD) receive harm reduction services including overdose education and naloxone, an opioid antagonist that can rapidly reverse an opioid overdose (SAMHSA 2024; ACOG 2017).
Substantial policy changes to promote naloxone access and large-scale community-driven interventions such as the Healing Communities Study have improved naloxone dissemination to at-risk populations alongside anti- naloxone stigma campaigns (Freeman et al., 2025). However, there remain barriers. Among individuals, stigma related to naloxone can negatively impact acceptance (Banks, Li, Park, Winograd, & Cavazos-Rehg, 2025; Bennett, Freeman, Des Jarlais, & Aronson, 2020). With regards to direct-to-consumer store uptake and sales of over-the-counter (OTC) naloxone, a recent study in four states highly affected by opioid overdose (KY, OH, MA, and NY) showed that the average cost for a 2-unit box was $45, less than 10% of stores as identified by NieselIQ retail data sold OTC naloxone, and there were particularly low sales in geographic areas with economic vulnerability (Gamon, Gaber, Saunders, & Zarkin, 2025). Within some local communities police have misunderstood state naloxone regulations and treated naloxone as drug paraphernalia seizing it from persons’ possession when leaving syringe support programs (Silwal et al. 2025). Taken together, these barriers point to the continued need to promote naloxone access through clinicians who see and treat people and their families affected by opioid use disorder.
Obtaining naloxone via an individual prescription through methadone or buprenorphine treatment, referred to as MOUD herein, can be challenging though too. One study of an intensive clinical pharmacist-led intervention increased naloxone co-prescription with buprenorphine to peripartum patients to 70% from baseline annual co-prescribing rates ranging from 17.7% to 55.8% over 2017–2021; however, improvements were not sustained beyond 3 months (Bechtol, Ramage, Krulikas, Futrell, & Caron, 2024). A survey of perinatal naloxone care practices developed with the Ohio Perinatal Quality Collaborative demonstrated that 49% of maternal care provider participants discussed or prescribed naloxone to pregnant patients with OUD and only 16% of pediatric provider participants provided naloxone information to the parents of their pediatric patients with prenatal opioid exposure (Nidey, Kaplan, Ford, Prasad, & Lannon, 2025).
MOUD reduces opioid overdose and all-cause mortality and treatment programs are critical places for patients to access naloxone. Notably, treatment retention is often sub-optimal, particularly in the peripartum period when there can be fear of social service agencies separating mother and child, increased stress of parenting and mental health issues, and reduced services post-delivery (Schauberger, Smid, Terplan, & Wright, 2025). Thus, developing interventions to improve naloxone uptake among peripartum individuals in MOUD treatment is critical because it is hard to predict when treatment discontinuation will occur and overdose risk will increase. Having naloxone prior to treatment discontinuation may help reduce risk of fatal overdose.
We adapted a brief personally tailored opioid overdose and MOUD educational interventional (TOME) for peripartum individuals based upon previous work among out-of-treatment adults using illicit opioids, which demonstrated the intervention increased treatment readiness and that 65% of participants used study-provided naloxone (Winhusen et al., 2020). TOME was evaluated within 131 peripartum adults receiving MOUD (Winhusen et al., 2025). The study found that TOME, relative to control, significantly improved MOUD and opioid-overdose knowledge in these peripartum adults, but it did not impact MOUD stigma. These are important findings because incorrect knowledge can cause harm. For instance, only ~30% of peripartum participants knew that responding to an overdose by placing a person in a bathtub of cold water would not help. This improved to 87.3% after the TOME intervention but remained without significant change in the control condition. In this study, free naloxone was offered to all participants affording the opportunity to conduct a secondary analysis to evaluate: 1) the effect of TOME, relative to control, on naloxone acceptance and 2) peripartum participant characteristics associated with the acceptance of a free naloxone kit. We hypothesized prior to conducting these exploratory analyses that naloxone acceptance would be higher among persons who received TOME than control because a) more learning occurred in TOME than control (Winhusen et al., 2025) and b) learning about one’s medical treatment and overdose risk factors, signs, and response may promote naloxone acceptance.
2. Methods
Detailed methods, including a consort diagram, are available in the primary study manuscript. (Winhusen et al., 2025). The study was approved by the University of Cincinnati Institutional Review Board.
Participants enrolled and provided informed consent from six clinical sites; five were academically affiliated and one was a non-profit community treatment center. They were age 18 years and older, currently pregnant or within 12 months post-partum and receiving MOUD. Prisoner status and current suicidal or homicidal ideation were exclusionary. Randomization occurred June – October 2024, with 67 randomized to TOME and 64 to control. All sites offered randomized participants free naloxone (#2 4mg intranasal dose units). Participants from one site that offered naloxone prior to the intervention (n=20) were excluded from analyses.
TOME participants received an individual 15-min session with a trained research staff member who had at least a bachelor’s degree. Research staff had a two-hour training on the TOME intervention including sample script for how to provide 1:1 feedback using each participant’s computer generated personally tailored report. The report listed the number of baseline opioid overdose and MOUD knowledge responses answered incorrectly and provided explanations for the correct answers (example feedback report displayed in Winhusen et al 2025). Control condition participants received three SAMHSA handouts: 1) “Opioid Overdose Prevention Toolkit: Safety Advice for Patients and Family Members”; 2) “Opioid Overdose Prevention Toolkit: Recovering from Opioid Overdose”; and 3) “Medication-Assisted Treatment for Opioid Addiction: Facts for Families and Friends”.
Baseline demographics included age, gender, race, ethnicity, and employment and marital status (Hamilton et al., 2011). Time (months) in methadone or buprenorphine treatment was recorded. Other baseline assessments included the Opioid Overdose and Treatment Awareness Survey (OOTAS), which had 41 true-false items (each scored 0 or 1) within four sections covering opioid-overdose signs, risk factors, responses, and MOUD misconceptions (Winhusen T, 2016). A summary score was calculated that was the percentage of correct items both for the MOUD section and for the combined opioid-overdose sections. The Methadone Maintenance Treatment Stigma Mechanisms Scale (MMT-SMS; 25 self-report items) assesses three types of stigma: 1) internalized (i.e., how the individual feels about themselves because of receiving MOUD); 2) anticipated (how individual thinks people will treat them in the future because of their MOUD); and 3) past (how individual has been treated by family, employers, healthcare workers due to their MOUD) (Smith et al., 2020). The word “methadone” was replaced with “buprenorphine” for participants receiving buprenorphine. Thoughts about Abstinence assessed participants’ perception of current desire to quit using drugs, chance of success in quitting, and difficulty to keep from using drugs (Hall, Havassy, & Wasserman, 1991). The Suicide and Homicide Screening Form assessed past 6 month and prior to the past 6-month presence of recurrent thoughts of death, suicidal ideation, plans, gestures, attempts, and recurrent homicidal ideation and plans (Hasin et al., 1996). The reasons for not accepting nalxone were self-reported with three answer options: “already has naloxone”, “not comfortable with naloxone administration”, and “other – specify reason”.
Treatment assignment and participant characteristics of those who accepted naloxone (n=90), those who declined naloxone due to already having it (n=14), and those who declined naloxone for other reasons (n=7) were compared using Fisher Exact test for binary and categorical measures and Kruskal-Wallis test for numeric measures. The two-group comparisons (those who accepted vs. declined for other reasons) were completed with Fisher Exact and Wilcoxon Rank Sum tests. Statistical significance was set at p<0.05. Odds ratios and subsequent confidence intervals were calculated directly from the raw data. Analyses were conducted using observed data without imputation for missing data. Less than 4% of data were missing.
3. Results
Table 1 shows participant demographic, treatment, knowledge, and stigma characteristics as a function of naloxone acceptance. Across the three groups, the mean age ranged from 31.1 to 33.0 years and the mean duration of time maintained on MOUD ranged from 11.3 – 16. 3 months for those receiving buprenorphine and 17.6–20 months for those receiving methadone. The majority were post-partum (57.7%), white (91.0%), non-Hispanic (91.0%), with at least a GED or high school diploma (77.5%), and screening negative for suicidality in the last 6 months (99.1%). The sample had a high percentage of correct answers to opioid overdose questions (greater than 79% correct) and high ratings of desire to quit drugs with high expected success.
TABLE 1.
Characteristics of Peripartum Participants by Naloxone Status at Baseline
| Accepted Naloxone n=90 | Did Not Accept (Already Had) n=14 | Did Not Accept (Other Reason) n=7 | |
|---|---|---|---|
| Treatment Arm = TOME, n (%)* | 48 (53.3%) | 7 (50.0%) | 1 (14.3%) |
| Age, years (SD) | 31.1 (5.0) | 32.4 (4.8) | 33.0 (4.1) |
| Currently pregnant, n (%) | 40 (44.4%) | 6 (42.9%) | 3 (42.9%) |
| Currently post-partumA, n (%) | 52 (58.4%) | 8 (57.1%) | 4 (57.1%) |
| Gender, n (%) | |||
| Cisgender | 89 (98.9%) | 14 (100.0%) | 7 (100.0%) |
| Transgender / non-binary | 1 (1.1%) | 0 (0.0%) | 0 (0.0%) |
| Race, n (%) | |||
| AA/ Black | 2 (2.2%) | 1 (7.1%) | 0 (0.0%) |
| American Indian or Alaskan Native | 2 (2.2%) | 0 (0.0%) | 0 (0.0%) |
| White | 82 (91.1%) | 12 (85.7%) | 7 (100.0%) |
| More than one race | 4 (4.4%) | 1 (7.1%) | 0 (0.0%) |
| Hispanic, n (%) | 10 (11.1%) | 0 (0.0%) | 0 (0.0%) |
| Education, n (%) | |||
| 6th grade or less | 1 (1.1%) | 0 (0.0%) | 0 (0.0%) |
| More than 6th grade --no diploma | 23 (25.6%) | 1 (7.1%) | 0 (0.0%) |
| Highschool or GED | 55 (61.1%) | 11 (78.6%) | 6 (85.7%) |
| Associates or higher degree | 11 (12.2%) | 2 (14.3%) | 1 (14.3%) |
| Marital Status, n (%) | |||
| Married / With partner | 34 (37.8%) | 9 (64.3%) | 5 (71.4%) |
| Separated/Divorced/Widowed | 16 (17.8%) | 1 (7.1%) | 0 (0.0%) |
| Never Married | 40 (44.4%) | 4 (28.6%) | 2 (28.6%) |
| Employment Status, n (%) | |||
| Working now | 27 (30.0%) | 3 (21.4%) | 2 (28.6%) |
| Temporarily laid off, sick or maternity leave | 9 (10.0%) | 2 (14.3%) | 2 (28.6%) |
| Unemployed, looking for work | 25 (27.8%) | 6 (42.9%) | 1 (14.3%) |
| Disabled, permanently or temporarily | 5 (5.6%) | 1 (7.1%) | 1 (14.3%) |
| Keeping house | 19 (21.1%) | 2 (14.3%) | 0 (0.0%) |
| Student | 4 (4.4%) | 0 (0.0%) | 0 (0.0%) |
| Other | 1 (1.1%) | 0 (0.0%) | 1 (14.3%) |
| In methadone treatment,, n (%) | 18 (20.0%) | 2 (14.3%) | 0 (0.0%) |
| In buprenorphine treatment,, n (%) | 72 (80.0%) | 12 (85.7%) | 7 (100.0%) |
| Current MOUD treatment duration, months (SD): | |||
| Methadone | 17.6 (10.6) | 20.0 (25.5) | |
| Buprenorphine | 16.3 (24.8) | 13.5 (21.4) | 11.3 (12.1) |
| PRISM Suicide itemsB, n (%): | |||
| Yes, in the last 6 months | 1 (1.1%) | 0 (0.0%) | 0 (0.0%) |
| Yes, more than 6 months ago | 23 (25.6%) | 3 (21.4%) | 1 (14.3%) |
| OOTAS, % correct (SD) | |||
| Opioid Overdose questions | 81.9% (6.3%) | 82.0% (5.5%) | 79.3% (6.1%) |
| MOUD questions** | 66.8% (13.8%) | 70.7% (16.4%) | 55.7% (12.7%) |
| Thoughts about AbstinenceC, mean (SD) | |||
| Desire to Quit Drugs | 8.8 (0.5) | 8.9 (0.4) | 8.9 (0.4) |
| Expected Success | 8.7 (0.7) | 8.6 (0.6) | 8.9 (0.4) |
| Expected Difficulty | 2.4 (2.6) | 1.6 (2.2) | 4.3 (3.6) |
| MOUD Treatment StigmaD, mean (SD) | |||
| Future Stigma | 2.3 (0.9) | 1.9 (0.8) | 2.7 (0.7) |
| Past Stigma | 2.3 (0.9) | 1.7 (0.5) | 2.3 (0.9) |
| Past Stigma – Family*** | 2.5 (1.2) | 1.5 (0.8) | 2.5 (1.2) |
| Past Stigma – Work**** | 2.0 (0.9) | 1.3 (0.4) | 1.9 (0.9) |
| Past Stigma -- Treatment | 2.4 (1.2) | 2.3 (1.2) | 2.5 (1.1) |
| Internalized Stigma | 1.8 (0.8) | 1.7 (0.7) | 2.1 (0.9) |
TOME: Personally Tailored Opioid-overdose and Medication for Opioid Use Disorder Education,
OOTAS: Opioid Overdose and Treatment Awareness Survey,
MOUD: Medication Treatment for Opioid Use Disorder
PRISM: Psychiatric Research Interview for Substance and Mental Disorders
Fisher Exact test comparing those accepting naloxone (n=90) to those not accepting for other reasons (n=7) resulted in P=0.0592, OR=6.857
Wilcoxen-Rank-Sum test resulted in P<0.05 comparing those accepting naloxone (n=90) to those not accepting naloxone for other reasons (n=7)
Kruskal-Wallis test resulted in P < 0.001 comparing all three groups;
Kruskal-Wallis test resulted in P < 0.05 comparing all three groups
Two participants were currently pregnant and within 12 months postpartum.
Yes indicates any thoughts of death, suicidal ideation, plan, gesture, or attempt.
Range is 0–9, where higher scores indicate greater desire, expected success, and expected difficulty.
Methadone Maintenance Treatment Stigma Mechanisms Scale: Range is 1–5, where higher scores indicate more stigma.
Among the 111 participants, 21 declined naloxone. Fourteen declined because they already had it, none declined due to being uncomfortable administering it, and seven declined for other specified reasons. The seven self-reported “other” reasons were: “I do not associate with anyone who is not in treatment or doing what they should be doing”; “I don’t want it in my house”, allergy to naloxone, not interested in receiving it, does not need it at this time, not around the type of people where would need naloxone, and did not know if could have naloxone on her.
Of the 90 participants accepting naloxone, 48 (53.3%) received TOME. Of the 7 who reported not having naloxone and declining to accept it, 1 (14.3%) received TOME. There was a non-statistically significant trend for TOME to increase the odds of naloxone acceptance (OR: 6.857, CI: 0.793, 59.291, p=0.0592).
Analyses showed statistically significant differences on family (p<0.001) and employer stigma (p<0.05) among those who accepted naloxone, declined it because they had it already, and declined it for “other” reasons. Specifically, the 14 participants who declined naloxone due to already having it had the lowest mean (SD) family [1.5 (0.8)] and employer [1.3 (0.4)] stigma ratings compared to the 90 who accepted naloxone [family stigma: 2.5 (1.2); employer stigma: 2.0 (0.9)] and the 7 who declined naloxone for “other” reasons [family stigma: 2.5 (1.2); employer stigma: 1.9 (0.9)]. In addition, those who accepted naloxone had a significantly higher percentage of correct answers (66.8%) to MOUD knowledge items than those who did not accept naloxone (55.7%) for “other” reasons (p<0.05). The results from the individual MOUD knowledge questions are included in Table 2.
TABLE 2.
Performance on Individual Medication for Opioid Use Disorder Questions as a Function of Naloxone Acceptance
| MOUD Item, % answering correctly | Accepted Naloxone (n=90) | Declined Naloxone (Already had it, n=14) | Declined Naloxone (Other reason (n=7) |
|---|---|---|---|
| 1. Methadone rots your teeth and bones. | 42.2% | 28.6% | 42.9% |
| 2. Methadone and buprenorphine are worse for your body than opioid abuse. | 95.6% | 100.0% | 100.0% |
| 3. With methadone or buprenorphine you have less risk of an opioid overdose. | 77.8% | 92.9% | 57.1% |
| 4. Most people getting treatment with methadone or buprenorphine only need one dose a day. | 54.4% | 71.4% | 57.1% |
| 5. Methadone and buprenorphine make people high or sleepy. | 60.0% | 78.6% | 28.6% |
| 6. Methadone and buprenorphine suppress your immune system. | 94.4% | 92.9% | 85.7% |
| 7. Taking less methadone or buprenorphine is always better than taking more. | 45.6% | 35.7% | 14.3% |
| 8. Methadone and buprenorphine are just substitutes for the opioid you are abusing. | 88.9% | 85.7% | 71.4% |
| 9. Methadone and buprenorphine are recommended treatments for pregnant persons with opioid use disorder. | 97.8% | 100.0% | 100.0% |
| 10. A problem with taking methadone or buprenorphine during pregnancy is that the baby may be born addicted. | 11.1% | 21.4% | 0.0% |
4. Discussion
This secondary analysis study showed that past family and employer stigma may be an important factor impacting naloxone acceptance because these types of stigma were lowest among participants who declined naloxone because they already had it. TOME demonstrated a trend toward promoting naloxone acceptance. Specifically, six of the seven people who declined for reasons other than having it already (e.g., naloxone allergy, did not know if they could have naloxone on them, did not affiliate with people who may need it) were in the control group. The only significant baseline difference between the 90 who accepted naloxone and the 7 who declined for “other” reasons was baseline MOUD knowledge.
The finding of lower past stigma in the 14 people who declined naloxone because they already had it and higher past stigma in the 7 who declined it because of “other” reasons such as not wanting it in their house or not needing it because they do not associate with people out of treatment is consistent with prior research reporting stigma as a barrier to naloxone acceptance (Bennett, Freeman, Des Jarlais, & Aronson, 2020). Baseline MOUD knowledge was significantly better among those accepting naloxone compared to those who declined for “other” reasons. Having better health literacy about ones’ illness and its treatment may make one more likely to accept naloxone to help someone else with the same illness. These results suggest that MOUD knowledge and family and employer stigma may influence willingness to have naloxone and thus, interventions aimed at improving MOUD knowledge and reducing these sources of stigma may be important targets for development. In addition to TOME, on-line resources aimed at improving MOUD health literacy in peripartum individuals are available (https://ctnlibrary.org/paths-oud-nida-ctn-di/).
It is encouraging that, not counting the 14 people who declined naloxone because they already had it, 90 of 97 participants accepted study naloxone and that TOME demonstrated a trend toward promoting naloxone acceptance. This may be due to TOME’s ability to increase MOUD and opioid-overdose knowledge (Winhusen TJ, 2025). A qualitative study found that an inability to accurately recognize an overdose was a potential barrier to naloxone acceptance (Bennett et al 2020).
This study has limitations including a small sample size and having mostly established patients in treatment for over six months with few declining naloxone, which limits generalizability and the ability to do more sophisticated analyses (e.g., regression). There were multiple comparisons such that there is risk for Type 1 error. We did not ask all patients if they had any naloxone at baseline so it is possible that some participants who accepted naloxone already had some naloxone, which may be advantageous (e.g., having one at home and one with them), but it does limit the understanding of the impact of the intervention among persons without naloxone. We also did not ask if participants carry or plan to carry naloxone with them, which is an important part of the naloxone cascade of care and we do not know the reasons for not having naloxone at baseline or for potential stigma related to accepting/carrying naloxone (Akhurst et al., 2024). Given these limitations, this study’s results should be viewed as preliminary providing important questions for follow-up upon in a future larger study powered on a naloxone acceptance/carrying outcome.
5. Conclusions
These results suggest further evaluation of brief tailored individual educational interventions to enhance naloxone acceptance. Stigma and MOUD knowledge may be important factors to measure and discuss with patients.
Highlights.
Participants were peripartum, taking medication for opioid use disorder treatment (MOUD)
Knowledge about MOUD and overdose was tested and naloxone was offered
A brief, computer-facilitated innovative intervention reviewed incorrect answers
The intervention trended towards increasing naloxone acceptance versus control
MOUD knowledge was significantly higher among those accepting naloxone
Acknowledgements
We wish to acknowledge the participation of the six clinical trial sites and their patients who participated in this study.
Sources of support/funding for the work:
This work was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Health through the NIH HEAL Initiative under award numbers UG1DA013732 to the University of Cincinnati (T. John Winhusen), UG1DA049444 (Adam Gordon and Gerald Cochran), UG1DA013727 (Kathleen Brady and Matthew Carpenter), UG1DA013720 (Jose Szapocznik, Daniel Feaster, and Lisa Metsch), and UG1DA049436 (Jane Liebschutz and Judith Feinberg). The Publications Committee of the National Drug Abuse Treatment Clinical Trials Network reviewed and gave approval for submission of this manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or its NIH HEAL Initiative.
Conflicts of interest/disclosures:
In the last three years, MRL has served as a research consultant to Braeburn Pharmaceuticals, Berkshire Biomedical, and Journey Colab and received an honorarium from Camurus for a research talk. JEC is supported by funds received by the University of Utah from Gilead Pharmaceuticals related to research of the treatment of Hepatitis C in pregnancy. In the last year JEC has been an advisor on Gilead Science Hepatitis C and pregnancy advisory committee. JEC also acts as a speaker for Braeburn Pharmaceuticals. All other authors report no conflicts.
Footnotes
Author contributions: CRediT
Lofwall – Investigation, methodology, visualization, Writing – first draft, review and editing
Kropp - Investigation, Methodology, Project administration, Supervision, Writing – review and editing
Charles - Investigation, Supervision, Writing – review & editing
Cochran - Investigation, supervision, writing—review and editing
Douaihy - Investigation, conceptualization, project administration, funding acquisition, writing-review and editing
Edwards - Investigation, writing- review and editing
Lewis – Data curation, Software, Formal analysis, Visualization, Writing—review and editing
Rosa- Supervision, writing-review and editing
Young - Investigation, project administration, supervision, writing-review and editing
Winhusen- Conceptualization, funding acquisition, supervision, writing-original draft
Declaration of generative AI and AI-assisted technologies in the writing process
These technologies were not used.
References
- Akhurst J, Price O, Sutherland R, Gibbs D, Dietze P, Bruno R, Agramunt S, Colledge-Frisby S, Lenton S, Salom C, Thomas N, & Peacock A (2024). Naloxone cascade of care among people who regularly inject drugs in Australia, 2020–2022. Int J Drug Policy, 133, 104572. doi: 10.1016/j.drugpo.2024.104572 [DOI] [PubMed] [Google Scholar]
- American College of Obstetricians and Gynecologists (2017). Opioid use and opioid use disorder in pregnancy. Committee Opinion 711. Retrieved from https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/08/opioid-use-and-opioid-use-disorder-in-pregnancy
- Banks DE, Li X, Park B, Winograd RP, & Cavazos-Rehg P (2025). Naloxone Stigma Among People Who Use Drugs: Characteristics and Associations With Stigma Toward Medication for Opioid Use Disorder. J Addict Med, 19(1), 68–74. doi: 10.1097/ADM.0000000000001377 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bechtol AC, Ramage M, Krulikas LJ, Futrell K, & Caron O (2024). Naloxone access in perinatal substance use disorder. J Am Pharm Assoc (2003), 64(3), 102026. doi: 10.1016/j.japh.2024.01.022 [DOI] [PubMed] [Google Scholar]
- Bennett AS, Freeman R, Des Jarlais DC, & Aronson ID (2020). Reasons People Who Use Opioids Do Not Accept or Carry No-Cost Naloxone: Qualitative Interview Study. JMIR Form Res, 4(12), e22411. doi: 10.2196/22411 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Freeman PR, Walley AY, Winhusen TJ, Oga EA, Villani J, Hunt T, … Bassel NE (2025). Effect of the Communities That HEAL Intervention on Overdose Education and Naloxone Distribution: A Cluster-Randomized, Wait-List Controlled Trial. Am J Public Health, 115(1), 83–94. doi: 10.2105/AJPH.2024.307845. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gammon DG, Gaber J, Saunders M, & Zarkin GA (2025). Estimates of first-year OTC naloxone sales in four U.S. states with high rates of opioid overdose deaths: KY, MA, NY, OH. J Subst Use Addict Treat, 209762. doi: 10.1016/j.josat.2025.209762 [DOI] [PubMed] [Google Scholar]
- Hall SM, Havassy BE, & Wasserman DA (1991). Effects of commitment to abstinence, positive moods, stress, and coping on relapse to cocaine use. J Consult Clin Psychol, 59(4), 526–532. doi: 10.1037//0022-006x.59.4.526 [DOI] [PubMed] [Google Scholar]
- Hamilton CM, Strader LC, Pratt JG, Maiese D, Hendershot T, Kwok RK, Hammond JA, Huggins W, Hackman D, Pan H, Nettles DS, Beaty TH, Farrer LA, Kraft P, Marazita ML, Ordovas JM, Pato CN, Spitz MR,…Haines J (2011). The PhenX Toolkit: get the most from your measures. Am J Epidemiol, 174(3), 253–260. doi: 10.1093/aje/kwr193 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Han B, Compton WM, Einstein EB, Elder E, & Volkow ND (2024). Pregnancy and Postpartum Drug Overdose Deaths in the US Before and During the COVID-19 Pandemic. JAMA Psychiatry, 81(3), 270–283. doi: 10.1001/jamapsychiatry.2023.4523 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hasin DS, Trautman KD, Miele GM, Samet S, Smith M, & Endicott J (1996). Psychiatric Research Interview for Substance and Mental Disorders (PRISM): reliability for substance abusers. Am J Psychiatry, 153(9), 1195–1201. doi: 10.1176/ajp.153.9.1195 [DOI] [PubMed] [Google Scholar]
- Nidey N, Kaplan HC, Ford S, Prasad M, & Lannon C (2025). Perinatal Naloxone Care Practices: Survey Results From Persons With OUD and Providers. J Addict Med, 19(1), 62–67. doi: 10.1097/ADM.0000000000001376 [DOI] [PubMed] [Google Scholar]
- Schauberger CW, Smid MC, Terplan M, & Wright TE (2025). Lessons from Maternal Mortality Reviews. How Addiction Care Providers can help improve Outcomes for Pregnant, Postpartum, and Parenting people. Subst Use Misuse, 60(3), 446–451. doi: 10.1080/10826084.2024.2422957 [DOI] [PubMed] [Google Scholar]
- Silwal A, Bohler R, Hunt T, Olvera RG, Lofwall MR, Cook CD, … Talbert JC (2025). Identifying and responding to policy-related barriers, facilitators, and misunderstandings in the HEALing communities study: A community-driven approach. Int J Drug Policy, 142, 104851. doi: 10.1016/j.drugpo.2025.104851 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Smith LR, Mittal ML, Wagner K, Copenhaver MM, Cunningham CO, & Earnshaw VA (2020). Factor structure, internal reliability and construct validity of the Methadone Maintenance Treatment Stigma Mechanisms Scale (MMT-SMS). Addiction, 115(2), 354–367. doi: 10.1111/add.14799 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Substance Abuse and Mental Health Services Administration (SAMHSA). Evidence-Based, Whole-Person Care for Pregnant People Who Have Opioid Use Disorder Advisory. Publication No. PEP23-02-01-002. Rockville, MD. Released 2023. Updated 2024. [Google Scholar]
- Winhusen T, T. J, Lewis D, Wilder CM, Lyons MS. (2016). Opioid Overdose and Treatment Awareness Survey (OOTAS) [Database record]. APA PsycTests. doi: 10.1037/t65687-000 [DOI] [Google Scholar]
- Winhusen T, Wilder C, Lyons MS, Theobald J, Kropp F, & Lewis D (2020). Evaluation of a personally-tailored opioid overdose prevention education and naloxone distribution intervention to promote harm reduction and treatment readiness in individuals actively using illicit opioids. Drug Alcohol Depend, 216, 108265. doi: 10.1016/j.drugalcdep.2020.108265 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Winhusen TJ, Kropp F, Smid MC, Young JL, Davies TH, Lewis D, … Lofwall MR (2025). Personally-tailored opioid-overdose and medication for opioid use disorder (MOUD) education (TOME) significantly increases MOUD and overdose knowledge in peripartum individuals: Results from a randomized controlled pilot trial. Drug Alcohol Depend, 275, 112795. doi: 10.1016/j.drugalcdep.2025.112795 [DOI] [PMC free article] [PubMed] [Google Scholar]
